WO2009021943A3 - Neues herstellverfahren - Google Patents

Neues herstellverfahren Download PDF

Info

Publication number
WO2009021943A3
WO2009021943A3 PCT/EP2008/060560 EP2008060560W WO2009021943A3 WO 2009021943 A3 WO2009021943 A3 WO 2009021943A3 EP 2008060560 W EP2008060560 W EP 2008060560W WO 2009021943 A3 WO2009021943 A3 WO 2009021943A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation process
novel preparation
mentioned
general formula
description
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/060560
Other languages
English (en)
French (fr)
Other versions
WO2009021943A2 (de
Inventor
Juergen Schnaubelt
Thomas Fachinger
Michael Konrad
Thomas Krueger
Joern Merten
Carsten Reichel
Svenja Renner
Rolf Schmid
Emanuel Stehle
Bianca Werner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Priority to AU2008288430A priority Critical patent/AU2008288430A1/en
Priority to US12/672,098 priority patent/US8288531B2/en
Priority to EP08803004A priority patent/EP2188275A2/de
Priority to BRPI0815419-8A2A priority patent/BRPI0815419A2/pt
Priority to CA2696257A priority patent/CA2696257A1/en
Priority to CN200880111400A priority patent/CN101821258A/zh
Priority to MX2010001512A priority patent/MX2010001512A/es
Priority to JP2010520554A priority patent/JP2010535838A/ja
Publication of WO2009021943A2 publication Critical patent/WO2009021943A2/de
Publication of WO2009021943A3 publication Critical patent/WO2009021943A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/96—Esters of carbonic or haloformic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)

Abstract

Gegenstand der vorliegenden Erfindung ist ein Verfahren zur Herstellung von Verbindungen der allgemeinen Formel (I) in der R1 und R2 wie in der Beschreibung erwähnt definiert sind, deren pharmazeutisch verträglichen Salze und den Solvaten davon, die ausgehend von Verbindungen der allgemeinen Formel (II) in der R1 wie in der Beschreibung erwähnt definiert ist, hergestellt werden können.
PCT/EP2008/060560 2007-08-13 2008-08-12 Neues herstellverfahren Ceased WO2009021943A2 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2008288430A AU2008288430A1 (en) 2007-08-13 2008-08-12 Novel preparation process
US12/672,098 US8288531B2 (en) 2007-08-13 2008-08-12 Preparation process
EP08803004A EP2188275A2 (de) 2007-08-13 2008-08-12 Neues herstellverfahren
BRPI0815419-8A2A BRPI0815419A2 (pt) 2007-08-13 2008-08-12 Método de produção
CA2696257A CA2696257A1 (en) 2007-08-13 2008-08-12 Novel preparation process
CN200880111400A CN101821258A (zh) 2007-08-13 2008-08-12 新的制备方法
MX2010001512A MX2010001512A (es) 2007-08-13 2008-08-12 Nuevo procedimiento de preparacion.
JP2010520554A JP2010535838A (ja) 2007-08-13 2008-08-12 新規調製方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007038251.2 2007-08-13
DE102007038251A DE102007038251A1 (de) 2007-08-13 2007-08-13 Neues Herstellverfahren

Publications (2)

Publication Number Publication Date
WO2009021943A2 WO2009021943A2 (de) 2009-02-19
WO2009021943A3 true WO2009021943A3 (de) 2009-04-30

Family

ID=39874112

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/060560 Ceased WO2009021943A2 (de) 2007-08-13 2008-08-12 Neues herstellverfahren

Country Status (16)

Country Link
US (1) US8288531B2 (de)
EP (1) EP2188275A2 (de)
JP (1) JP2010535838A (de)
KR (1) KR20100052531A (de)
CN (1) CN101821258A (de)
AR (1) AR068807A1 (de)
AU (1) AU2008288430A1 (de)
BR (1) BRPI0815419A2 (de)
CA (1) CA2696257A1 (de)
CL (1) CL2008002377A1 (de)
DE (1) DE102007038251A1 (de)
MX (1) MX2010001512A (de)
PE (1) PE20090515A1 (de)
TW (1) TW200918518A (de)
UY (1) UY31282A1 (de)
WO (1) WO2009021943A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007038250A1 (de) * 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
CN103601722B (zh) * 2013-09-13 2016-03-02 南京华威医药科技开发有限公司 新型抗肿瘤化合物
CN105777615A (zh) * 2016-04-07 2016-07-20 戊言医药科技（上海）有限公司 4-吗啉代哌啶的制备方法
US10835535B2 (en) 2016-05-07 2020-11-17 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
EP3470394B1 (de) * 2016-06-09 2022-01-26 Yuki Gosei Kogyo Co., Ltd. Verfahren zur herstellung von 4-(piperidin-4-yl)morpholin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100009A1 (de) * 2005-03-23 2006-09-28 Boehringer Ingelheim International Gmbh Cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
EP1801093A1 (de) * 2005-12-22 2007-06-27 Saltigo GmbH Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-Phenyl-Propion-Säuren

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904421D0 (sv) * 1999-12-03 1999-12-03 Astra Ab New compounds
ES2350340T3 (es) * 2002-08-30 2011-01-21 F. Hoffmann-La Roche Ag Nuevos compuestos de 2-aril-tiazol como agonistas de pparalfa y ppargamma.
EP1619187A1 (de) 2004-07-23 2006-01-25 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung von 3-(4-Piperidinyl)- 2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-on
EP1770086A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100009A1 (de) * 2005-03-23 2006-09-28 Boehringer Ingelheim International Gmbh Cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
EP1801093A1 (de) * 2005-12-22 2007-06-27 Saltigo GmbH Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-Phenyl-Propion-Säuren

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FREIFELDER M ET AL: "Reductions with Ruthenium. Its Use in the Hydrogenation of Pyridines", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON.; US, vol. 26, 1 January 1961 (1961-01-01), pages 3805 - 3808, XP002237303, ISSN: 0022-3263 *
PAULINE C TING ET AL: "Synthesis of substituted 4(Z)-(methoxyimino)pentyl-1-piperidines as dual NK1/NK2 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,, vol. 11, 1 January 2001 (2001-01-01), pages 491 - 494, XP002508634 *

Also Published As

Publication number Publication date
CL2008002377A1 (es) 2009-10-23
JP2010535838A (ja) 2010-11-25
WO2009021943A2 (de) 2009-02-19
BRPI0815419A2 (pt) 2015-02-03
MX2010001512A (es) 2010-03-10
US8288531B2 (en) 2012-10-16
DE102007038251A1 (de) 2009-02-19
UY31282A1 (es) 2009-03-31
AR068807A1 (es) 2009-12-09
PE20090515A1 (es) 2009-05-28
CA2696257A1 (en) 2009-02-19
CN101821258A (zh) 2010-09-01
AU2008288430A1 (en) 2009-02-19
EP2188275A2 (de) 2010-05-26
KR20100052531A (ko) 2010-05-19
TW200918518A (en) 2009-05-01
US20110087021A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
WO2009122436A3 (en) An improved process for the preparation of morphinane analogues
WO2009002427A3 (en) Methods of synthesizing cinacalcet and salts thereof
WO2009053854A3 (en) Polymorphs of dasatinib and process for preparation thereof
WO2007147771A3 (en) Tetralin and indane derivatives and uses thereof
WO2010076810A3 (en) A process for the preparation of gefitinib
WO2012042534A3 (en) Preparation of r-sitagliptin and intermediates thereof
WO2010116140A8 (en) New process for preparing hydroxylamines and medicaments
WO2012015681A3 (en) Drug-ligand conjugates, synthesis thereof, and intermediates thereto
WO2010140765A2 (ko) 로수바스타틴의 신규한 제조방법, 이 제조에 유용한 중간체 화합물 및 그의 제조방법
WO2006113509A3 (en) Quinobenzoxazine analogs and methods of using thereof
WO2009047499A3 (en) Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes
WO2009056707A8 (fr) Dérivés de l'ind0l-2-0ne disubstitues en 3, leur preparation et leur application en thérapeutique
AU2010321366A8 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
WO2009021943A3 (de) Neues herstellverfahren
WO2009075516A3 (en) Process for preparing pantoprazole sodium sesquihydrate
WO2007017728A3 (en) Novel heterocyclic compounds
WO2008059513A3 (en) Compounds suitable as modulators of hdl
WO2008015133A3 (en) Process for preparing amidrazones
WO2012015687A3 (en) Drug-ligand conjugates, synthesis thereof, and intermediates thereto
WO2007143014A3 (en) Methods for preparing glutamic acid derivatives and intermediates thereof
MY150428A (en) Tricyclic n-heteroaryl-carboxamide derivatives, preparation thereof and therapeutic use of same
WO2010122580A3 (en) Piperidine derivatives as inhibitors of renin
MX2009001168A (es) Nuevo procedimiento de preparacion.
WO2008006720A3 (en) Crystalline nemorubicin hydrochloride
WO2008099418A3 (en) An improved process for preparing bupropion hydrochloride

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880111400.2

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2008803004

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08803004

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 203661

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/001512

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2696257

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 975/DELNP/2010

Country of ref document: IN

Ref document number: 12010500345

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2010520554

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 583531

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008288430

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20107005352

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010108949

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2008288430

Country of ref document: AU

Date of ref document: 20080812

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12672098

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0815419

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100212